Endocannabinoid Signaling Collapse Mediates Stress-Induced Amygdalo-Cortical Strengthening.
Animals
Anxiety
/ complications
Arachidonic Acids
/ metabolism
Basolateral Nuclear Complex
/ metabolism
Endocannabinoids
/ metabolism
Glutamic Acid
/ metabolism
Glycerides
/ metabolism
Male
Mice
Neural Pathways
/ metabolism
Prefrontal Cortex
/ metabolism
Restraint, Physical
Stress, Psychological
/ complications
Synaptic Transmission
/ physiology
2-arachidonoylglycerol
amygdala
anxiety
cannabinoid
cannabis
glutamate
optogenetics
posttraumatic stress disorder
prefrontal cortex
stress
Journal
Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320
Informations de publication
Date de publication:
18 03 2020
18 03 2020
Historique:
received:
17
05
2019
revised:
25
11
2019
accepted:
18
12
2019
pubmed:
18
1
2020
medline:
15
7
2020
entrez:
18
1
2020
Statut:
ppublish
Résumé
Functional coupling between the amygdala and the dorsomedial prefrontal cortex (dmPFC) has been implicated in the generation of negative affective states; however, the mechanisms by which stress increases amygdala-dmPFC synaptic strength and generates anxiety-like behaviors are not well understood. Here, we show that the mouse basolateral amygdala (BLA)-prelimbic prefrontal cortex (plPFC) circuit is engaged by stress and activation of this pathway in anxiogenic. Furthermore, we demonstrate that acute stress exposure leads to a lasting increase in synaptic strength within a reciprocal BLA-plPFC-BLA subcircuit. Importantly, we identify 2-arachidonoylglycerol (2-AG)-mediated endocannabinoid signaling as a key mechanism limiting glutamate release at BLA-plPFC synapses and the functional collapse of multimodal 2-AG signaling as a molecular mechanism leading to persistent circuit-specific synaptic strengthening and anxiety-like behaviors after stress exposure. These data suggest that circuit-specific impairment in 2-AG signaling could facilitate functional coupling between the BLA and plPFC and the translation of environmental stress to affective pathology.
Identifiants
pubmed: 31948734
pii: S0896-6273(19)31090-6
doi: 10.1016/j.neuron.2019.12.024
pmc: PMC7992313
mid: NIHMS1569423
pii:
doi:
Substances chimiques
Arachidonic Acids
0
Endocannabinoids
0
Glycerides
0
Glutamic Acid
3KX376GY7L
glyceryl 2-arachidonate
8D239QDW64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1062-1076.e6Subventions
Organisme : NIMH NIH HHS
ID : F31 MH114363
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA013514
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107435
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA039080
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS052819
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043982
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests S.P. has received research support from H. Lundbeck A/S in the past 3 years. S.P. is a consultant for Psy Therapeutics.
Références
Neuropsychopharmacology. 2009 Dec;34(13):2699-709
pubmed: 19675536
Nat Rev Neurosci. 2015 Jun;16(6):317-31
pubmed: 25991441
Neuroimage. 2010 Jan 1;49(1):963-70
pubmed: 19683585
Mol Pharmacol. 2004 Nov;66(5):1260-4
pubmed: 15272052
J Pharmacol Exp Ther. 2009 Nov;331(2):591-7
pubmed: 19666749
Cereb Cortex. 2011 Jul;21(7):1667-73
pubmed: 21127016
Nat Neurosci. 2010 May;13(5):592-600
pubmed: 20348918
Depress Anxiety. 2009;26(11):984-92
pubmed: 19750552
Neuropharmacology. 2008 Jan;54(1):108-16
pubmed: 17675104
Curr Protoc Neurosci. 2017 Jul 5;80:4.39.1-4.39.24
pubmed: 28678399
Neuron. 2018 Oct 24;100(2):436-452
pubmed: 30359607
Cell Rep. 2016 Aug 2;16(5):1237-1242
pubmed: 27452462
Occup Environ Med. 2018 Dec;75(12):904-915
pubmed: 30377257
Neuropsychopharmacology. 2009 Dec;34(13):2733-45
pubmed: 19710634
Nat Rev Neurosci. 2015 Dec;16(12):705-18
pubmed: 26585799
Eur Neuropsychopharmacol. 2012 Sep;22(9):664-71
pubmed: 22325231
Neurosci Biobehav Rev. 2017 May;76(Pt A):56-66
pubmed: 28434588
Endocrinology. 2004 Dec;145(12):5431-8
pubmed: 15331569
Biol Psychiatry. 2017 Oct 1;82(7):488-499
pubmed: 28438413
Neuropsychopharmacology. 2014 Jun;39(7):1763-76
pubmed: 24476943
Nat Neurosci. 2017 Jun;20(6):824-835
pubmed: 28436980
Neuropsychopharmacology. 2018 Jan;43(1):80-102
pubmed: 28745306
Cell. 2014 Jun 19;157(7):1535-51
pubmed: 24949967
Elife. 2016 Mar 24;5:
pubmed: 27011354
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
pubmed: 2308954
Nat Neurosci. 2015 Oct;18(10):1376-85
pubmed: 26404712
Neuropsychopharmacology. 2005 Mar;30(3):508-15
pubmed: 15525997
Cell Rep. 2017 Nov 7;21(6):1426-1433
pubmed: 29117549
Nature. 1997 Aug 21;388(6644):773-8
pubmed: 9285589
Synapse. 2004 Jan;51(1):32-58
pubmed: 14579424
Pharmacol Res. 2011 Sep;64(3):226-34
pubmed: 21600985
Physiol Rev. 2009 Jan;89(1):309-80
pubmed: 19126760
Neuron. 2014 Jan 22;81(2):428-37
pubmed: 24462103
Nat Neurosci. 2017 Aug;20(8):1172-1179
pubmed: 28671695
Neurosci Biobehav Rev. 2014 May;42:1-8
pubmed: 24525267
Biol Psychiatry. 2009 Dec 15;66(12):1075-82
pubmed: 19748076
Int J Neuropsychopharmacol. 2014 Aug;17(8):1193-206
pubmed: 24438603
Semin Immunol. 2014 Oct;26(5):380-8
pubmed: 24882055
Nat Neurosci. 2011 Nov 06;14(12):1542-7
pubmed: 22057189
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):107-120
pubmed: 30564886
Proc Natl Acad Sci U S A. 2012 Oct 16;109 Suppl 2:17180-5
pubmed: 23045648
Neuron. 2013 Aug 21;79(4):658-64
pubmed: 23972595
Brain Neurosci Adv. 2018 May 08;2:2398212818774223
pubmed: 30167466
Nature. 2010 Jun 10;465(7299):788-92
pubmed: 20473285
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Nature. 2001 Mar 29;410(6828):588-92
pubmed: 11279497
J Neurosci. 2013 Sep 25;33(39):15333-42
pubmed: 24068800
Neuropsychopharmacology. 2011 Dec;36(13):2750-61
pubmed: 21849983
J Neurosci. 2017 Jul 19;37(29):6851-6868
pubmed: 28630250
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 2;90:37-42
pubmed: 30419321
Neuropharmacology. 2018 Sep 1;139:68-75
pubmed: 29959957
Front Neurosci. 2018 Jul 31;12:479
pubmed: 30108473
Nat Neurosci. 2015 Oct;18(10):1353-63
pubmed: 26404710
Nat Rev Neurosci. 2015 Oct;16(10):642
pubmed: 26333516
Lancet Psychiatry. 2014 Sep 1;1(4):294-302
pubmed: 25722962
Annu Rev Neurosci. 2012;35:529-58
pubmed: 22524785
Eur J Neurosci. 2014 Jun;39(11):1810-23
pubmed: 24819022
PLoS One. 2007 Aug 08;2(8):e709
pubmed: 17684555
Vitam Horm. 2017;103:193-279
pubmed: 28061971
Annu Rev Psychol. 2016;67:239-61
pubmed: 26442668
J Clin Invest. 2011 Apr;121(4):1424-8
pubmed: 21364278
Neuron. 2015 Mar 4;85(5):942-58
pubmed: 25741722
Nat Commun. 2017 Mar 28;8:14782
pubmed: 28348378
Elife. 2018 Feb 22;7:
pubmed: 29469809
Nat Rev Neurosci. 2018 Sep;19(9):535-551
pubmed: 30054570
Cereb Cortex. 2008 Jun;18(6):1292-301
pubmed: 17921459
J Neurosci. 2010 Aug 18;30(33):11188-96
pubmed: 20720126
Biol Mood Anxiety Disord. 2013 Oct 22;3(1):19
pubmed: 24286185
Neuron. 2015 Mar 18;85(6):1319-31
pubmed: 25754825
Prostaglandins Leukot Essent Fatty Acids. 2019 Jan;140:51-56
pubmed: 30553404
Neurosci Biobehav Rev. 2014 May;42:116-31
pubmed: 24582908
Neuroscience. 2016 May 3;321:197-209
pubmed: 26204817
Cell Rep. 2014 Dec 11;9(5):1644-1653
pubmed: 25466252
Nature. 2013 Feb 14;494(7436):238-42
pubmed: 23354054